JP2009503107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009503107A5 JP2009503107A5 JP2008525195A JP2008525195A JP2009503107A5 JP 2009503107 A5 JP2009503107 A5 JP 2009503107A5 JP 2008525195 A JP2008525195 A JP 2008525195A JP 2008525195 A JP2008525195 A JP 2008525195A JP 2009503107 A5 JP2009503107 A5 JP 2009503107A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- alkyl
- thiazol
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- -1 thiocarbamoyl Chemical group 0.000 claims 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000001589 carboacyl group Chemical group 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000005024 alkenyl aryl group Chemical group 0.000 claims 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims 7
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- 125000003435 aroyl group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000003981 vehicle Substances 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000012752 auxiliary agent Substances 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- JOMOAMJPPUFTSI-UHFFFAOYSA-N 4-(4-chlorophenyl)-1,3-thiazole-2-carboxylic acid Chemical compound S1C(C(=O)O)=NC(C=2C=CC(Cl)=CC=2)=C1 JOMOAMJPPUFTSI-UHFFFAOYSA-N 0.000 claims 2
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 108010035597 sphingosine kinase Proteins 0.000 claims 2
- XXZQDEHSQNRYCH-UHFFFAOYSA-N 1-(1,3-benzothiazol-2-yl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2SC3=CC=CC=C3N=2)=C1 XXZQDEHSQNRYCH-UHFFFAOYSA-N 0.000 claims 1
- DGLLHELENVMDCN-UHFFFAOYSA-N 1-(5-chloro-1,3-benzoxazol-2-yl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2OC3=CC=C(Cl)C=C3N=2)=C1 DGLLHELENVMDCN-UHFFFAOYSA-N 0.000 claims 1
- AXFYUQKIYMVFPR-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 AXFYUQKIYMVFPR-UHFFFAOYSA-N 0.000 claims 1
- OECHURISVRKTLG-UHFFFAOYSA-N 2,4-dichloro-n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(NC(=O)C=2C(=CC(Cl)=CC=2)Cl)=N1 OECHURISVRKTLG-UHFFFAOYSA-N 0.000 claims 1
- NLTOQIMGHXWPMK-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(NC(=O)CC=2C=C3OCOC3=CC=2)=N1 NLTOQIMGHXWPMK-UHFFFAOYSA-N 0.000 claims 1
- JHVALSRTUOVNLL-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C(CCN)C=C1Br JHVALSRTUOVNLL-UHFFFAOYSA-N 0.000 claims 1
- CFXGLQURELTJPS-UHFFFAOYSA-N 2-chloro-n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(Cl)C(=O)NC(SC=1)=NC=1C1=CC=C(Cl)C=C1 CFXGLQURELTJPS-UHFFFAOYSA-N 0.000 claims 1
- MKEWYPDSJFOTDY-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(NC(=O)C=CC=2C=C3OCOC3=CC=2)=N1 MKEWYPDSJFOTDY-UHFFFAOYSA-N 0.000 claims 1
- NMNPWVCDFOCDQH-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1CN(C)CCC1NC(=O)C1=CC=CC(C=2C=CC(Cl)=CC=2)=C1 NMNPWVCDFOCDQH-UHFFFAOYSA-N 0.000 claims 1
- WLJSOFDFVHVTOM-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-(2-pyridin-4-ylethyl)benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC(C(=O)NCCC=2C=CN=CC=2)=C1 WLJSOFDFVHVTOM-UHFFFAOYSA-N 0.000 claims 1
- GHBZMRXTLNSNRV-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-(4-hydroxyphenyl)benzamide Chemical compound C1=CC(O)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(Cl)=CC=2)=C1 GHBZMRXTLNSNRV-UHFFFAOYSA-N 0.000 claims 1
- ZOVNKLPTYAKFKG-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-(pyridin-4-ylmethyl)benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC(C(=O)NCC=2C=CN=CC=2)=C1 ZOVNKLPTYAKFKG-UHFFFAOYSA-N 0.000 claims 1
- SUBHPZIAKSTONB-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide Chemical compound CN1CCCC1CCNC(=O)C1=CC=CC(C=2C=CC(Cl)=CC=2)=C1 SUBHPZIAKSTONB-UHFFFAOYSA-N 0.000 claims 1
- KVLXOQWRFPIDSA-UHFFFAOYSA-N 4-(4-chlorophenyl)-n,n-bis(3-phenylpropyl)-1,3-thiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CSC(N(CCCC=2C=CC=CC=2)CCCC=2C=CC=CC=2)=N1 KVLXOQWRFPIDSA-UHFFFAOYSA-N 0.000 claims 1
- OQKOGDJJSOSKPB-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(2-ethylsulfanylethyl)-1,3-thiazole-2-carboxamide Chemical compound S1C(C(=O)NCCSCC)=NC(C=2C=CC(Cl)=CC=2)=C1 OQKOGDJJSOSKPB-UHFFFAOYSA-N 0.000 claims 1
- CNABCJTVHNTWHU-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(2-morpholin-4-ylethyl)-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCCN2CCOCC2)=N1 CNABCJTVHNTWHU-UHFFFAOYSA-N 0.000 claims 1
- AKWXPICOKLLXBU-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(2-pyridin-4-ylethyl)-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCCC=2C=CN=CC=2)=N1 AKWXPICOKLLXBU-UHFFFAOYSA-N 0.000 claims 1
- OHPOJONOXDZHAG-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(2h-tetrazol-5-yl)-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NC=2NN=NN=2)=N1 OHPOJONOXDZHAG-UHFFFAOYSA-N 0.000 claims 1
- GWOXSEIVOLIYKK-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(3,5-difluorophenyl)-1,3-thiazole-2-carboxamide Chemical compound FC1=CC(F)=CC(NC(=O)C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 GWOXSEIVOLIYKK-UHFFFAOYSA-N 0.000 claims 1
- ZTFOJPVGBWIMLA-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(3-pyrrolidin-1-ylpropyl)-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCCCN2CCCC2)=N1 ZTFOJPVGBWIMLA-UHFFFAOYSA-N 0.000 claims 1
- KOIHYAURWODXTR-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(4-methylpiperazin-1-yl)-1,3-thiazole-2-carboxamide Chemical compound C1CN(C)CCN1NC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 KOIHYAURWODXTR-UHFFFAOYSA-N 0.000 claims 1
- DMSUBVRSIXBFJX-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-(pyridin-4-ylmethyl)-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCC=2C=CN=CC=2)=N1 DMSUBVRSIXBFJX-UHFFFAOYSA-N 0.000 claims 1
- MRWIBGMGTLOEQY-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(2,5-difluorophenoxy)methyl]-1,3-thiazol-2-amine Chemical compound FC1=CC=C(F)C(OCNC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 MRWIBGMGTLOEQY-UHFFFAOYSA-N 0.000 claims 1
- OJDWUDAKHJRDNN-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(3,4,5-trifluorophenyl)methyl]-1,3-thiazole-2-carboxamide Chemical compound FC1=C(F)C(F)=CC(CNC(=O)C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 OJDWUDAKHJRDNN-UHFFFAOYSA-N 0.000 claims 1
- VHDKRCKKTULFEB-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(3,4-difluorophenyl)methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 VHDKRCKKTULFEB-UHFFFAOYSA-N 0.000 claims 1
- YHYONVFXLNNQGM-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(3,5-difluorophenoxy)methyl]-1,3-thiazol-2-amine Chemical compound FC1=CC(F)=CC(OCNC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 YHYONVFXLNNQGM-UHFFFAOYSA-N 0.000 claims 1
- QOBTYVQRMWHRPF-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(3,5-difluorophenyl)methoxymethyl]-1,3-thiazol-2-amine Chemical compound FC1=CC(F)=CC(COCNC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 QOBTYVQRMWHRPF-UHFFFAOYSA-N 0.000 claims 1
- ZENLJWIPVJEMJW-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(3,5-difluorophenyl)methyl]-1,3-thiazole-2-carboxamide Chemical compound FC1=CC(F)=CC(CNC(=O)C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 ZENLJWIPVJEMJW-UHFFFAOYSA-N 0.000 claims 1
- DQASMKMLMHDJJU-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(4-methylsulfanylphenyl)methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(SC)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 DQASMKMLMHDJJU-UHFFFAOYSA-N 0.000 claims 1
- KPKPPIXNQBLHTR-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(4-methylsulfonylphenyl)methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 KPKPPIXNQBLHTR-UHFFFAOYSA-N 0.000 claims 1
- ZCBVFZDCDHNHCF-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(4-phenoxyphenyl)methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCC=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 ZCBVFZDCDHNHCF-UHFFFAOYSA-N 0.000 claims 1
- RTGHXPPMBKVCTM-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[(4-phenylphenyl)methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCC=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 RTGHXPPMBKVCTM-UHFFFAOYSA-N 0.000 claims 1
- IFWOHNVBUYLOEI-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[1-(4-chlorophenyl)ethyl]-1,3-thiazole-2-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C(C)NC(=O)C(SC=1)=NC=1C1=CC=C(Cl)C=C1 IFWOHNVBUYLOEI-UHFFFAOYSA-N 0.000 claims 1
- UXLPKDLHMWRDIJ-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[2-(1-methylpyrrolidin-2-yl)ethyl]-1,3-thiazole-2-carboxamide Chemical compound CN1CCCC1CCNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 UXLPKDLHMWRDIJ-UHFFFAOYSA-N 0.000 claims 1
- PZJLDKJCCCDDIW-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[2-(3-phenoxyphenyl)ethyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCCC=2C=C(OC=3C=CC=CC=3)C=CC=2)=N1 PZJLDKJCCCDDIW-UHFFFAOYSA-N 0.000 claims 1
- ADBSXJWMIUZKJS-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound FC1=CC(C(F)(F)F)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 ADBSXJWMIUZKJS-UHFFFAOYSA-N 0.000 claims 1
- CAZFHBYGNLQFER-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CNC(=O)C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 CAZFHBYGNLQFER-UHFFFAOYSA-N 0.000 claims 1
- WZVIYVPBQQMXMD-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(CNC(=O)C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 WZVIYVPBQQMXMD-UHFFFAOYSA-N 0.000 claims 1
- SXOHLKXSDBTUFP-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[4-(dimethylamino)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 SXOHLKXSDBTUFP-UHFFFAOYSA-N 0.000 claims 1
- UICBMRBPNWZWRK-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[4-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 UICBMRBPNWZWRK-UHFFFAOYSA-N 0.000 claims 1
- SSWAMBVBVKXNLQ-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[4-(trifluoromethyl)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 SSWAMBVBVKXNLQ-UHFFFAOYSA-N 0.000 claims 1
- RKVHRUFKAKZOLX-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(CNC(=O)C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 RKVHRUFKAKZOLX-UHFFFAOYSA-N 0.000 claims 1
- ZSORJFUSMDSAKG-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1,3-thiazole-2-carboxamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZSORJFUSMDSAKG-UHFFFAOYSA-N 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- PZCQOEHBQGSXSO-UHFFFAOYSA-N [2,3-di(butanoyloxy)-5-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]phenyl] butanoate Chemical compound CCCC(=O)OC1=C(OC(=O)CCC)C(OC(=O)CCC)=CC(C(=O)NC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 PZCQOEHBQGSXSO-UHFFFAOYSA-N 0.000 claims 1
- HDGAEBHQSHBUSQ-UHFFFAOYSA-N [2-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]phenyl] butanoate Chemical compound CCCC(=O)OC1=CC=CC=C1C=CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 HDGAEBHQSHBUSQ-UHFFFAOYSA-N 0.000 claims 1
- AXHSMWBCELHSRU-UHFFFAOYSA-N [2-amino-4-[2-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-2-oxoethyl]phenyl] butanoate Chemical compound C1=C(N)C(OC(=O)CCC)=CC=C1CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 AXHSMWBCELHSRU-UHFFFAOYSA-N 0.000 claims 1
- XAWIVBYCTSRRRP-UHFFFAOYSA-N [3-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]phenyl] butanoate Chemical compound CCCC(=O)OC1=CC=CC(C=CC(=O)NC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 XAWIVBYCTSRRRP-UHFFFAOYSA-N 0.000 claims 1
- SGSIZWOUVBWSNA-UHFFFAOYSA-N [4-[2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-2-oxoethyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1CC(=O)NC1=NC2=CC=C(Cl)C=C2S1 SGSIZWOUVBWSNA-UHFFFAOYSA-N 0.000 claims 1
- BFWSBGOFOQEUCD-UHFFFAOYSA-N [4-[2-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-2-oxoethyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 BFWSBGOFOQEUCD-UHFFFAOYSA-N 0.000 claims 1
- VEJJENMKYJGMPH-UHFFFAOYSA-N [4-[2-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-2-oxoethyl]-2-nitrophenyl] butanoate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)CCC)=CC=C1CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 VEJJENMKYJGMPH-UHFFFAOYSA-N 0.000 claims 1
- SSBHMRZURYSKSW-UHFFFAOYSA-N [4-[3-[[4-(4-bromophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1C=CC(=O)NC1=NC(C=2C=CC(Br)=CC=2)=CS1 SSBHMRZURYSKSW-UHFFFAOYSA-N 0.000 claims 1
- BXVHSOIZPUQVPC-UHFFFAOYSA-N [4-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]-2-methoxyphenyl] acetate Chemical compound C1=C(OC(C)=O)C(OC)=CC(C=CC(=O)NC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 BXVHSOIZPUQVPC-UHFFFAOYSA-N 0.000 claims 1
- GYHDLXIGKBXZCB-UHFFFAOYSA-N [4-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1C=CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 GYHDLXIGKBXZCB-UHFFFAOYSA-N 0.000 claims 1
- CQQBWOIWNVPGMC-UHFFFAOYSA-N [4-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1C=CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 CQQBWOIWNVPGMC-UHFFFAOYSA-N 0.000 claims 1
- GSQKMIOWSNVXPJ-UHFFFAOYSA-N [4-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]phenyl] butanoate Chemical compound C1=CC(OC(=O)CCC)=CC=C1C=CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 GSQKMIOWSNVXPJ-UHFFFAOYSA-N 0.000 claims 1
- AJDAQOUMGFGTKY-UHFFFAOYSA-N [4-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxopropyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1CCC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 AJDAQOUMGFGTKY-UHFFFAOYSA-N 0.000 claims 1
- RKYZLOKLFBYNAG-UHFFFAOYSA-N [4-[3-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1C=CC(=O)NC1=NC(C=2C=CC(F)=CC=2)=CS1 RKYZLOKLFBYNAG-UHFFFAOYSA-N 0.000 claims 1
- RIHJWPHTRZTFCB-UHFFFAOYSA-N [4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1C(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 RIHJWPHTRZTFCB-UHFFFAOYSA-N 0.000 claims 1
- QDCQMJDZTKMTKX-UHFFFAOYSA-N [5-[3-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-3-oxoprop-1-enyl]-2-methoxyphenyl] butanoate Chemical compound C1=C(OC)C(OC(=O)CCC)=CC(C=CC(=O)NC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 QDCQMJDZTKMTKX-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001309 chloro group Chemical class Cl* 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- RCSJMEGGOPRTDG-UHFFFAOYSA-N ethyl 4-(4-chlorophenyl)-1,3-thiazole-2-carboxylate Chemical compound S1C(C(=O)OCC)=NC(C=2C=CC(Cl)=CC=2)=C1 RCSJMEGGOPRTDG-UHFFFAOYSA-N 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000003584 mesangial cell Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- PJOTWTYXJMRJIX-UHFFFAOYSA-N n,n-dibenzyl-4-(4-chlorophenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CSC(N(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=N1 PJOTWTYXJMRJIX-UHFFFAOYSA-N 0.000 claims 1
- HKJJPXRPGGUAFC-UHFFFAOYSA-N n-(5-chloro-1,3-benzothiazol-2-yl)-2-hydroxybenzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC2=CC(Cl)=CC=C2S1 HKJJPXRPGGUAFC-UHFFFAOYSA-N 0.000 claims 1
- ZBAJZKSZLHAXSR-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)-2-nitrobenzamide Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)NC1=NC2=CC(Cl)=CC=C2O1 ZBAJZKSZLHAXSR-UHFFFAOYSA-N 0.000 claims 1
- CWQLTSJJIKPWQU-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=CC(=O)NC1=NC2=CC(Cl)=CC=C2O1 CWQLTSJJIKPWQU-UHFFFAOYSA-N 0.000 claims 1
- ZNKFCGUTZNEQSK-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)-3-fluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2OC3=CC=C(Cl)C=C3N=2)=C1 ZNKFCGUTZNEQSK-UHFFFAOYSA-N 0.000 claims 1
- NGDZHBKPLBIBLA-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)-3-phenylprop-2-enamide Chemical compound N=1C2=CC(Cl)=CC=C2OC=1NC(=O)C=CC1=CC=CC=C1 NGDZHBKPLBIBLA-UHFFFAOYSA-N 0.000 claims 1
- ZOYMPXSCRCDSIH-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)hexadecanamide Chemical compound ClC1=CC=C2OC(NC(=O)CCCCCCCCCCCCCCC)=NC2=C1 ZOYMPXSCRCDSIH-UHFFFAOYSA-N 0.000 claims 1
- OSAPDKRXPGSKIC-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)tetradecanamide Chemical compound ClC1=CC=C2OC(NC(=O)CCCCCCCCCCCCC)=NC2=C1 OSAPDKRXPGSKIC-UHFFFAOYSA-N 0.000 claims 1
- KRYZHHULCVDOGI-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)undec-10-enamide Chemical compound ClC1=CC=C2OC(NC(=O)CCCCCCCCC=C)=NC2=C1 KRYZHHULCVDOGI-UHFFFAOYSA-N 0.000 claims 1
- RYHNEQUGSCDFDK-UHFFFAOYSA-N n-[(2-chloro-4-fluorophenyl)methyl]-4-(4-chlorophenyl)-1,3-thiazole-2-carboxamide Chemical compound ClC1=CC(F)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 RYHNEQUGSCDFDK-UHFFFAOYSA-N 0.000 claims 1
- NDLNALYMAVXTTH-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-4-(4-chlorophenyl)-1,3-thiazole-2-carboxamide Chemical compound C1=C(Cl)C(F)=CC=C1CNC(=O)C1=NC(C=2C=CC(Cl)=CC=2)=CS1 NDLNALYMAVXTTH-UHFFFAOYSA-N 0.000 claims 1
- FVWOCCIWYVMMNI-UHFFFAOYSA-N n-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(4-chlorophenyl)-1,3-thiazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(C(=O)NCCC=2C=C3OCOC3=CC=2)=N1 FVWOCCIWYVMMNI-UHFFFAOYSA-N 0.000 claims 1
- NIQLUZNVNVUMRS-UHFFFAOYSA-N n-[3-(tert-butylamino)propyl]-4-(4-chlorophenyl)-1,3-thiazole-2-carboxamide Chemical compound S1C(C(=O)NCCCNC(C)(C)C)=NC(C=2C=CC(Cl)=CC=2)=C1 NIQLUZNVNVUMRS-UHFFFAOYSA-N 0.000 claims 1
- UXIXSAQBYMBLQN-UHFFFAOYSA-N n-[4-(3-chlorophenyl)-1,3-thiazol-2-yl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-enamide Chemical compound C1=C(O)C(OC)=CC(C=CC(=O)NC=2SC=C(N=2)C=2C=C(Cl)C=CC=2)=C1 UXIXSAQBYMBLQN-UHFFFAOYSA-N 0.000 claims 1
- ABXQBPOPTGAOMF-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ABXQBPOPTGAOMF-UHFFFAOYSA-N 0.000 claims 1
- JRANGDRPLDRFCR-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-fluoro-4-(trifluoromethyl)benzamide Chemical compound FC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 JRANGDRPLDRFCR-UHFFFAOYSA-N 0.000 claims 1
- CNBIZPHXLRILDD-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-(2,4-difluorophenyl)propanamide Chemical compound FC1=CC(F)=CC=C1CCC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 CNBIZPHXLRILDD-UHFFFAOYSA-N 0.000 claims 1
- FPAJSHXFBGCNQQ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-(3,4-dimethoxyphenyl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 FPAJSHXFBGCNQQ-UHFFFAOYSA-N 0.000 claims 1
- FFEOUXIJYSBSRJ-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=CC(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 FFEOUXIJYSBSRJ-UHFFFAOYSA-N 0.000 claims 1
- ZXJMMWRIJMLNSV-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-fluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 ZXJMMWRIJMLNSV-UHFFFAOYSA-N 0.000 claims 1
- JSXNIUIBVUVOJT-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-phenylprop-2-enamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(NC(=O)C=CC=2C=CC=CC=2)=N1 JSXNIUIBVUVOJT-UHFFFAOYSA-N 0.000 claims 1
- VLNZEFLXKYQTSC-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 VLNZEFLXKYQTSC-UHFFFAOYSA-N 0.000 claims 1
- IUCAKSGIJLKFQO-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hexadecanamide Chemical compound S1C(NC(=O)CCCCCCCCCCCCCCC)=NC(C=2C=CC(Cl)=CC=2)=C1 IUCAKSGIJLKFQO-UHFFFAOYSA-N 0.000 claims 1
- HGVRTLKWHDIQEP-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]octadec-9-enamide Chemical compound S1C(NC(=O)CCCCCCCC=CCCCCCCCC)=NC(C=2C=CC(Cl)=CC=2)=C1 HGVRTLKWHDIQEP-UHFFFAOYSA-N 0.000 claims 1
- JHUUKIFPNQYKRT-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]tetradecanamide Chemical compound S1C(NC(=O)CCCCCCCCCCCCC)=NC(C=2C=CC(Cl)=CC=2)=C1 JHUUKIFPNQYKRT-UHFFFAOYSA-N 0.000 claims 1
- NFBGMXLDRLJJTE-UHFFFAOYSA-N n-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]undec-10-enamide Chemical compound C1=CC(Cl)=CC=C1C1=CSC(NC(=O)CCCCCCCCC=C)=N1 NFBGMXLDRLJJTE-UHFFFAOYSA-N 0.000 claims 1
- PDCXKBIPIVXHNK-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-chlorophenyl)-1,3-thiazole-2-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CNC(=O)C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 PDCXKBIPIVXHNK-UHFFFAOYSA-N 0.000 claims 1
- HXZVQFJBLWVBLC-UHFFFAOYSA-N n-[[3-(4-chlorophenyl)phenyl]methyl]-1-pyridin-4-ylmethanamine Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC(CNCC=2C=CN=CC=2)=C1 HXZVQFJBLWVBLC-UHFFFAOYSA-N 0.000 claims 1
- VVEJHOWTLIKUDJ-UHFFFAOYSA-N n-[[3-(4-chlorophenyl)phenyl]methyl]-2-(1-methylpyrrolidin-2-yl)ethanamine Chemical compound CN1CCCC1CCNCC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1 VVEJHOWTLIKUDJ-UHFFFAOYSA-N 0.000 claims 1
- QQDAIBUEPKCZLS-UHFFFAOYSA-N n-benzyl-4-(4-chlorophenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1C1=CSC(NCC=2C=CC=CC=2)=N1 QQDAIBUEPKCZLS-UHFFFAOYSA-N 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 **c1nc(*)c[s]1 Chemical compound **c1nc(*)c[s]1 0.000 description 5
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70560805P | 2005-08-04 | 2005-08-04 | |
| PCT/US2006/030327 WO2007019251A2 (en) | 2005-08-04 | 2006-08-03 | Sphingosine kinase inhibitors and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009503107A JP2009503107A (ja) | 2009-01-29 |
| JP2009503107A5 true JP2009503107A5 (enExample) | 2009-09-17 |
Family
ID=37433959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525195A Pending JP2009503107A (ja) | 2005-08-04 | 2006-08-03 | スフィンゴシンキナーゼ阻害剤およびそれらの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20070032531A1 (enExample) |
| EP (1) | EP1928848A2 (enExample) |
| JP (1) | JP2009503107A (enExample) |
| AU (1) | AU2006278592A1 (enExample) |
| CA (1) | CA2617788A1 (enExample) |
| IL (1) | IL188932A0 (enExample) |
| WO (1) | WO2007019251A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324237B2 (en) * | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| US8709015B2 (en) * | 2008-03-10 | 2014-04-29 | DePuy Synthes Products, LLC | Bilateral vertebral body derotation system |
| EP2107054A1 (en) * | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Antiproliferative compounds and therapeutic uses thereof |
| DE102008029734A1 (de) | 2008-06-23 | 2009-12-24 | Merck Patent Gmbh | Thiazolyl-piperidinderivate |
| EP2166094A1 (en) | 2008-09-23 | 2010-03-24 | Ecole Normale Superieure De Lyon | Methods for prolonging the health benefits triggered by a dietary restriction using a sphingosine kinase inhibitor |
| SI2411395T1 (sl) | 2009-03-23 | 2013-07-31 | Glenmark Pharmaceuticals S.A. | Furopirimidindionski derivati kot TRPA1 modulatorji |
| GB0905525D0 (en) * | 2009-03-31 | 2009-05-13 | Univ Leiden | Compounds and uses |
| JP2013513628A (ja) | 2009-12-14 | 2013-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | スフィンゴシンキナーゼの阻害薬 |
| KR101713453B1 (ko) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| SG183853A1 (en) * | 2010-03-17 | 2012-10-30 | Taivex Therapeutics Inc | Modulators of hec1 activity and methods therefor |
| CA2808307C (en) * | 2010-08-16 | 2022-06-21 | Allergan, Inc. | Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
| MA34957B1 (fr) | 2011-02-23 | 2014-03-01 | Lupin Ltd | Derives heteroaryle a titre modulateurs des nachr alpha 7 |
| WO2012166859A2 (en) * | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| DE102011083283A1 (de) * | 2011-09-23 | 2013-03-28 | Beiersdorf Ag | Heteroalkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Heteroalkylamidothiazolen |
| DE102011083271A1 (de) * | 2011-09-23 | 2013-03-28 | Beiersdorf Ag | Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen |
| US11071736B2 (en) | 2011-11-21 | 2021-07-27 | Taivex Therapeutics Corporation | Modulators of HEC1 activity and methods therefor |
| CN103159686A (zh) * | 2011-12-09 | 2013-06-19 | 天津市国际生物医药联合研究院 | 一种hiv-1蛋白酶的脲类抑制剂 |
| EP2822946A1 (en) | 2012-03-06 | 2015-01-14 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| NZ701721A (en) | 2012-06-08 | 2016-03-31 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4-arylthiazole compounds and their salts |
| CN103772376B (zh) * | 2012-10-24 | 2017-01-11 | 中国医学科学院医药生物技术研究所 | 取代的苯并-1,3-杂唑类化合物、其制备方法及用途 |
| EP2945936A1 (en) | 2012-11-12 | 2015-11-25 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| DE102013226711A1 (de) * | 2013-12-19 | 2015-06-25 | Beiersdorf Ag | Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| JP6615876B2 (ja) * | 2014-06-26 | 2019-12-04 | モナシュ ユニヴァーシティ | 酵素相互作用薬剤 |
| US10525021B2 (en) | 2014-11-18 | 2020-01-07 | Rutgers, The State University Of New Jersey | Mitochondrial uncouplers for treatment of metabolic diseases and cancer |
| US11026918B2 (en) | 2014-11-24 | 2021-06-08 | The Board Of Trustees Of The University Of Illinois | Method of preventing or treating a pulmonary disease or condition |
| CA2980801A1 (en) | 2015-04-24 | 2016-10-27 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US11028061B2 (en) * | 2015-07-27 | 2021-06-08 | Sanford Burnham Prebys Medical Discovery Institute | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof |
| CA3003611C (en) | 2015-11-04 | 2022-11-01 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| WO2017097216A1 (zh) * | 2015-12-07 | 2017-06-15 | 杭州雷索药业有限公司 | 五元杂环酰胺类wnt通路抑制剂 |
| GB2550363A (en) * | 2016-05-16 | 2017-11-22 | Avexxin As | Compound |
| CN110330452A (zh) * | 2019-06-12 | 2019-10-15 | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 四氢吡咯烷类化合物或其药学上可接受的盐及其制备方法和应用 |
| KR102732033B1 (ko) * | 2019-07-26 | 2024-11-20 | 아주대학교산학협력단 | Tlr7 및 tlr9의 신호전달 경로를 억제하는 신규한 소분자 화합물 및 그 용도 |
| CN114502541B (zh) * | 2019-10-02 | 2024-06-07 | 克洛索科学公司 | 诱导抗老化基因klotho的表达的化合物及其用途 |
| US20240376087A1 (en) * | 2021-11-16 | 2024-11-14 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. | Pyrazole amide based compounds and uses against breast cancer thereof |
| WO2025163462A1 (ko) * | 2024-02-02 | 2025-08-07 | 삼진제약주식회사 | 헤테로고리를 갖는 mrgprx2((mas-related g-protein coupled receptor member x2) 길항제 유도체와 이의 용도 |
| KR20250144822A (ko) * | 2024-03-27 | 2025-10-13 | 동국대학교 산학협력단 | 신규 옥사졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| CN118812459B (zh) * | 2024-07-04 | 2025-10-03 | 四川省医学科学院·四川省人民医院 | 含苯并噻唑或苯并恶唑的化合物、其制备方法及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3094462A (en) * | 1961-09-18 | 1963-06-18 | Mcneilab Inc | Therapeutic reaction complex for muscle relaxation |
| US4171364A (en) * | 1971-10-01 | 1979-10-16 | Eli Lilly And Company | N-heterocyclic ureas as immune regulants |
| AU2001236698A1 (en) * | 2000-02-07 | 2001-08-14 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| KR20030017569A (ko) * | 2000-06-28 | 2003-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카르베딜올 |
| US7220764B2 (en) * | 2002-06-17 | 2007-05-22 | The Pennsylvania State University Research Foundation | Sphingosine kinase inhibitors |
| WO2004005267A2 (en) * | 2002-07-03 | 2004-01-15 | Janssen Pharmaceutica, N.V. | Heteroaryl compounds useful in treating inflammatory disorders |
| EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7163937B2 (en) * | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US8324237B2 (en) * | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| US20060270631A1 (en) * | 2005-05-26 | 2006-11-30 | Smith Charles D | Methods for the treatment and prevention of angiogenic diseases |
-
2006
- 2006-08-03 CA CA002617788A patent/CA2617788A1/en not_active Abandoned
- 2006-08-03 WO PCT/US2006/030327 patent/WO2007019251A2/en not_active Ceased
- 2006-08-03 JP JP2008525195A patent/JP2009503107A/ja active Pending
- 2006-08-03 AU AU2006278592A patent/AU2006278592A1/en not_active Abandoned
- 2006-08-03 US US11/462,153 patent/US20070032531A1/en not_active Abandoned
- 2006-08-03 EP EP06800721A patent/EP1928848A2/en not_active Withdrawn
-
2008
- 2008-01-22 IL IL188932A patent/IL188932A0/en unknown
-
2009
- 2009-11-30 US US12/627,812 patent/US20100137315A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009503107A5 (enExample) | ||
| JP2004504301A5 (enExample) | ||
| JP2005531520A5 (enExample) | ||
| RU2009118825A (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1ГИДРОКСИЭТИЛ)ФЕНОЛА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2015517981A5 (enExample) | ||
| US10195213B2 (en) | Chemical entities that kill senescent cells for use in treating age-related disease | |
| JP2016506387A5 (enExample) | ||
| RU2015113746A (ru) | Замещенные сульфонамиды | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2007505127A5 (enExample) | ||
| HRP20141190T1 (hr) | Disupstituirani derivati piridina kao antikancerogena sredstva | |
| JP2004529931A5 (enExample) | ||
| JP2009528273A5 (enExample) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2007514003A5 (enExample) | ||
| KR960014125A (ko) | 헤테로사이클 화합물, 이들의 제조방법 및 용도 | |
| CA2299139A1 (en) | 4-phenyl-pyridine derivatives | |
| JP2004518691A (ja) | Ｐｄｅ４アイソザイムの阻害剤として有効なチアゾリル−、オキサゾリル−、ピロリル−、イミダゾリル−酸アミド誘導体 | |
| JP2010526145A5 (enExample) | ||
| JP2006519258A5 (enExample) | ||
| JP2012506446A5 (enExample) | ||
| RU2007146798A (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2013530240A5 (enExample) | ||
| JP2008507532A5 (enExample) | ||
| JP2008500284A5 (enExample) |